| Name | Title | Contact Details |
|---|
Janssen Research and Development is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. Relypsa was founded in October 2007 and is headquartered in Redwood City, Calif. In 2015, we received FDA approval for our first medicine, which was developed based on our polymer technology platform for the treatment of hyperkalemia. In September 2016, Relypsa became a Vifor Pharma company. Today, we have more than 400 employees united by a passion for improving people’s lives.
Loxo Oncology is committed to the discovery, development, and commercialization of targeted cancer therapies with best-in-class potential. Our diverse pipeline reflects the convergence of proven therapeutic technologies with emerging insights into the underlying susceptibilities of cancer and drug resistance. It is an exciting time to develop cancer drugs. Diagnostic methods are yielding strong clues about which cancer features are actionable, “driver alterations,” in contrast to those merely along for the ride as “passenger alterations.” In the last five years, these insights have transformed the standard of care in melanoma, lung cancer and other cancers. Picking a target is just the first step in building a cancer drug. Good chemists build good drugs. The physical properties of a compound have much to do with its ultimate success or failure. Is it stable? Is it soluble? Is it absorbed? Does it reach its target? Does it engage the target? Does it cause toxicity elsewhere in the body before it achieves maximum efficacy in the cancer? In our opinion, drugs that achieve excellent exposure in the body and are highly specific for their intended targets have the highest chances of success. Once an attractive target is selected and a drug with best-in-class properties is constructed, setting up the right clinical development plan is of utmost importance. Our goal is to generate a clinical path that reflects the underlying scientific hypothesis that made the drug interesting in the first place. This often means developing the drug in a population of patients whose tumors possess a specific vulnerability targeted by the drug. Loxo Oncology was built around a team of full-time professionals and engaged scientific advisors who are aligned in choosing the most actionable targets, and pursuing them through disciplined clinical trial approaches. Our license and collaboration agreement with Array Biopharma and our experienced team allow us to construct drugs with best-in-class properties from the ground up.
Levant Technologies is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prodesse is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.